Enliven Therapeutics (ELVN) AI Stock Analysis

• Market Cap: $842.39M
• Dividend Yield: N/A
• Average Volume (3M): 318.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 12.85%
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 73
• Industry: Biotechnology
• EPS (TTM): -1.90
• Shares Outstanding: 49,004,425
• 10 Day Avg. Volume: 449,029
• 30 Day Avg. Volume: 318,641
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -15.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $38.00
• Price Target Upside: 122.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Enliven Therapeutics shows significant challenges typical of early-stage biotechnology firms, with negative financial performance and a weak technical outlook. The strong liquidity position slightly offsets these issues, but the reliance on external financing and lack of profitability create a high-risk environment. The technical indicators further suggest bearish market sentiment.

Positive Factors

Efficacy and Safety Profile

Previous preclinical and clinical data underscored ELVN-001's highly competitive efficacy and safety profile.

Financial Stability

The company has a strong cash position with cash, cash equivalents, and marketable securities totaling $313.4 million, providing a cash runway into mid-2027.

Market Opportunity

ELVN-001 is designed as a follow-on therapy post Novartis' Scemblix, which has demonstrated success with $689 million in sales revenue, highlighting the potential market opportunity.

Negative Factors

Development Costs

HER2 is a competitive space and the cost of development is going to be substantially high in NSCLC and metastatic breast cancer.

Market Perception

The market is viewing the HER2 program as a free option, and Enliven may seek strategic partnership or licensing agreements for their HER2 asset, which would add non-dilutive cash.

Short Interest

Short Interest stands at 23.3% of the float, indicating a significant portion of the market is betting against the stock.

Enliven Therapeutics Business Overview & Revenue Model

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

How the Company Makes Money

Enliven Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, licensing agreements, and potential milestone payments as their drug candidates progress through clinical trials. Once a therapeutic product receives regulatory approval, Enliven Therapeutics generates revenue through product sales, either directly or via distribution agreements with strategic partners. Additionally, the company may engage in collaborations for research and development, which can provide upfront payments and ongoing royalties based on sales performance.

Enliven Therapeutics Financial Statement Overview

Summary

Enliven Therapeutics is in the development stage, typical of biotechnology firms, characterized by a lack of revenue and consistent financial losses. The strong liquidity position aids in sustaining operations, but the company remains reliant on external financing. Financial stability is gradually improving, but profitability remains a long-term challenge.

Income Statement

Enliven Therapeutics has shown a consistent pattern of negative revenue, gross profit, and net income, indicating significant challenges in generating sales and managing costs. The lack of revenue growth and persistent losses highlight the company's early-stage nature in the biotechnology sector, where long development cycles are common.

Balance Sheet

The balance sheet reflects strong liquidity with substantial cash reserves and no debt, supporting operational needs. However, negative stockholders' equity in previous years and current low total liabilities suggest potential financial instability. The company's equity ratio has improved recently, indicating better capital management.

Cash Flow

Cash flow statements indicate negative operating cash flows and free cash flows, which is typical for a biotechnology firm in the development phase. The company has maintained substantial financing activities, reflecting reliance on external capital to support operations. The operating cash flow to net income ratio is below optimal levels, underscoring challenges in converting income to cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-297.00K	-622.00K	-99.00K	-97.00K
	EBIT
-104.55M	-83.53M	-38.79M	-24.76M	-9.32M
	EBITDA
-104.55M	-81.93M	-38.58M	-24.65M	-9.27M
	Net Income Common Stockholders
-89.02M	-71.58M	-37.75M	-24.72M	-18.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
313.44M	253.15M	75.54M	110.02M	130.37M
	Total Assets
325.76M	271.87M	83.30M	113.33M	131.00M
	Total Debt
0.00	335.00K	323.00K	159.00K	105.00K
	Net Debt
-124.12M	-99.81M	-75.21M	-109.86M	-130.26M
	Total Liabilities
15.91M	25.96M	160.12M	156.22M	151.31M
	Stockholders Equity
309.85M	245.91M	-76.83M	-42.89M	-20.30M
Cash Flow		Free Cash Flow
-73.24M	-61.42M	-32.69M	-19.32M	-8.99M
	Operating Cash Flow
-73.19M	-61.27M	-32.08M	-19.13M	-8.53M
	Investing Cash Flow
-36.00M	-148.41M	-612.00K	-191.00K	-461.00K
	Financing Cash Flow
133.16M	234.29M	-1.80M	-1.02M	130.51M

Enliven Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Negative. The current price of 17.05 is below the 20-day moving average (MA) of 18.90, below the 50-day MA of 20.23, and below the 200-day MA of 23.21, indicating a bearish trend. The MACD of -1.25 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 49.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELVN.

Enliven Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARDX	60 Neutral	$1.09B	―	-23.01%	―	168.06%	44.66%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
GERN	46 Neutral	$796.14M	―	-66.09%	―	32387.34%	15.93%
NTLA	41 Neutral	$776.38M	―	-54.00%	―	59.55%	3.09%
SYRE	38 Underperform	$765.87M	2.31	-42.90%	―	-100.00%	94.68%
PLSE	35 Underperform	$1.11B	―	-67.31%	―	―	-1.00%
ELVN	34 Underperform	$842.39M	―	-32.04%	―	―	12.85%